SG92630A1 - Pyridazino quinoline compounds - Google Patents
Pyridazino quinoline compoundsInfo
- Publication number
- SG92630A1 SG92630A1 SG9900943A SG1999000943A SG92630A1 SG 92630 A1 SG92630 A1 SG 92630A1 SG 9900943 A SG9900943 A SG 9900943A SG 1999000943 A SG1999000943 A SG 1999000943A SG 92630 A1 SG92630 A1 SG 92630A1
- Authority
- SG
- Singapore
- Prior art keywords
- phenyl
- deriv
- substd
- opt
- furyl
- Prior art date
Links
- BOYBQQBDCOIBIR-UHFFFAOYSA-N pyrido[2,3-f]cinnoline Chemical class N1=CC=C2C3=NC=CC=C3C=CC2=N1 BOYBQQBDCOIBIR-UHFFFAOYSA-N 0.000 title 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000002947 alkylene group Chemical group 0.000 abstract 2
- 125000005605 benzo group Chemical group 0.000 abstract 2
- 125000002541 furyl group Chemical group 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 125000004076 pyridyl group Chemical group 0.000 abstract 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 abstract 1
- 241000689227 Cora <basidiomycete fungus> Species 0.000 abstract 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000003302 alkenyloxy group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 125000005133 alkynyloxy group Chemical group 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000005010 perfluoroalkyl group Chemical group 0.000 abstract 1
- OHZYAOYVLLHTGW-UHFFFAOYSA-N pyrido[3,2-c]pyridazine Chemical class C1=CN=NC2=CC=CN=C21 OHZYAOYVLLHTGW-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001544 thienyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Quinoline Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB939321854A GB9321854D0 (en) | 1993-10-22 | 1993-10-22 | Pyridazino quinoline compounds |
| GB9417171A GB9417171D0 (en) | 1994-08-25 | 1994-08-25 | Pyridazino quinoline compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG92630A1 true SG92630A1 (en) | 2002-11-19 |
Family
ID=26303731
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG9900943A SG92630A1 (en) | 1993-10-22 | 1994-10-20 | Pyridazino quinoline compounds |
| SG1996007261A SG59971A1 (en) | 1993-10-22 | 1994-10-20 | Pyridazino quinoline compounds |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG1996007261A SG59971A1 (en) | 1993-10-22 | 1994-10-20 | Pyridazino quinoline compounds |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US5744471A (cs) |
| EP (2) | EP0724583B1 (cs) |
| JP (1) | JP3583132B2 (cs) |
| KR (1) | KR100261209B1 (cs) |
| CN (1) | CN1053189C (cs) |
| AT (2) | ATE198072T1 (cs) |
| AU (2) | AU688393B2 (cs) |
| CA (1) | CA2171332A1 (cs) |
| CZ (1) | CZ292311B6 (cs) |
| DE (2) | DE69426422T2 (cs) |
| DK (2) | DK1004582T3 (cs) |
| ES (2) | ES2241513T3 (cs) |
| FI (2) | FI113865B (cs) |
| GB (1) | GB9420590D0 (cs) |
| GR (1) | GR3035080T3 (cs) |
| HU (1) | HUT74161A (cs) |
| IL (1) | IL111266A (cs) |
| MY (2) | MY124316A (cs) |
| NO (1) | NO306995B1 (cs) |
| NZ (2) | NZ275472A (cs) |
| PL (1) | PL180679B1 (cs) |
| PT (2) | PT724583E (cs) |
| RU (1) | RU2168511C2 (cs) |
| SG (2) | SG92630A1 (cs) |
| SI (2) | SI1004582T1 (cs) |
| SK (1) | SK282491B6 (cs) |
| TW (1) | TW406082B (cs) |
| UA (1) | UA60291C2 (cs) |
| WO (1) | WO1995011244A1 (cs) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL111266A (en) * | 1993-10-22 | 2002-03-10 | Zeneca Ltd | 2-HETEROARYL OR 2-ARYLPYRIDAZINO [4,5-b] QUINOLINE - 1, 10 - DIONES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
| GB9422894D0 (en) * | 1994-11-12 | 1995-01-04 | Zeneca Ltd | Pyridazino quinoline compounds |
| US6214826B1 (en) | 1994-11-12 | 2001-04-10 | Zeneca Limited | Pyridazino quinoline compounds |
| GB9507318D0 (en) * | 1995-04-07 | 1995-05-31 | Zeneca Ltd | Alpha substituted pyridazino quinoline compounds |
| SI1244662T1 (cs) * | 1999-12-23 | 2005-08-31 | Astrazeneca Ab | |
| WO2001047923A1 (en) * | 1999-12-23 | 2001-07-05 | Astrazeneca Ab | Compounds and methods for the treatment of pain |
| AU2566201A (en) * | 1999-12-23 | 2001-07-09 | Astrazeneca Ab | Compounds and methods for the treatment of pain |
| EP1248621A1 (en) * | 1999-12-23 | 2002-10-16 | AstraZeneca AB | Method and composition for the treatment of pain |
| EP1244453A1 (en) * | 1999-12-23 | 2002-10-02 | AstraZeneca AB | Method and composition for the treatment of pain |
| US6943165B2 (en) * | 1999-12-23 | 2005-09-13 | Astrazeneca Ab | Compound and method for the treatment of pain |
| JP2003519146A (ja) * | 1999-12-23 | 2003-06-17 | アストラゼネカ・アクチエボラーグ | 痛みの処置のための方法および組成物 |
| US6787547B2 (en) | 1999-12-23 | 2004-09-07 | Astrazeneca Ab | Compound and method for the treatment of pain |
| US20030176435A1 (en) * | 2002-12-17 | 2003-09-18 | Brown Dean Gordon | Compounds and methods for the treatment of pain |
| WO2001047926A1 (en) * | 1999-12-23 | 2001-07-05 | Astrazeneca Ab | Compounds and methods for the treatment of pain |
| JP2003519149A (ja) * | 1999-12-23 | 2003-06-17 | アストラゼネカ・アクチエボラーグ | 痛みの処置のための化合物および方法 |
| US6730675B2 (en) | 1999-12-23 | 2004-05-04 | Astrazeneca Ab | Compounds and methods for the treatment of pain |
| US6403818B1 (en) | 2000-02-28 | 2002-06-11 | Eisai Co., Ltd. | Process for producing α-hydroxy-carbonyl compound |
| EP1325003B1 (en) * | 2000-09-29 | 2006-08-02 | AstraZeneca AB | 7-chloro-4-hydroxy-2-(2-pyridylethyl)-1,2,5,10-tetrahydropyridazino 4,5-b|quinoline-1,10-dione and the use thereof for the treatment of pain |
| AU2002214441A1 (en) * | 2000-09-29 | 2002-04-08 | Astrazeneca Ab | 1,2,5,10-tetrahydropyridazino(4,5-b)quinoline-1,10-diones and their use for the treatment of pain |
| AU2001292498A1 (en) * | 2000-09-29 | 2002-04-08 | Astrazeneca Ab | 1,2,5,10-tetrahydropyridazino(4,5-b)quinoline-1,10-diones and their use for the treatment of pain |
| JP2004509965A (ja) | 2000-09-29 | 2004-04-02 | アストラゼネカ・アクチエボラーグ | １，２，５，１０−テトラヒドロピリダジノ［４，５−ｂ］キノリン−１，１０−ジオン及び疼痛治療のためのその使用 |
| WO2002096879A1 (en) | 2001-05-31 | 2002-12-05 | Sanofi-Synthelabo | Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands |
| US8592421B2 (en) | 2003-08-04 | 2013-11-26 | Valery Khazhmuratovich Zhilov | Cyclic bioisosters of purine system derivatives and a pharmaceutical composition based thereon |
| US8354427B2 (en) | 2004-06-24 | 2013-01-15 | Vertex Pharmaceutical Incorporated | Modulators of ATP-binding cassette transporters |
| ES2628026T3 (es) | 2004-06-24 | 2017-08-01 | Vertex Pharmaceuticals Incorporated | Moduladores de transportadores del casete de unión a ATP |
| CN101374849A (zh) * | 2005-12-24 | 2009-02-25 | 沃泰克斯药物股份有限公司 | 作为abc转运蛋白调控剂的喹啉-4-酮衍生物 |
| WO2007079139A2 (en) | 2005-12-28 | 2007-07-12 | Vertex Pharmaceuticals, Inc. | Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
| US12458635B2 (en) | 2008-08-13 | 2025-11-04 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
| EP3330255B1 (en) | 2009-03-20 | 2020-12-09 | Vertex Pharmaceuticals Incorporated | Process for making modulators of cystic fibrosis transmembrane conductance regulator |
| US8802700B2 (en) | 2010-12-10 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
| MX2014010253A (es) | 2012-02-27 | 2014-11-12 | Vertex Pharma | Composicion farmaceutica y administraciones de la misma. |
| ES2702288T3 (es) | 2014-10-07 | 2019-02-28 | Vertex Pharma | Co-cristales de moduladores de regulador de conductancia transmembrana de la fibrosis quística |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0516297B1 (en) * | 1991-05-09 | 1996-10-30 | Zeneca Limited | Pyridazinediones and their use in the treatment of neurological disorders |
| EP0512817B1 (en) * | 1991-05-09 | 1997-02-19 | Zeneca Limited | Pyridazinedione derivatives, their preparation and pharmaceutical applications |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8814458D0 (en) * | 1988-06-17 | 1988-07-20 | Wyeth John & Brother Ltd | Heterocyclic compounds |
| IL111266A (en) * | 1993-10-22 | 2002-03-10 | Zeneca Ltd | 2-HETEROARYL OR 2-ARYLPYRIDAZINO [4,5-b] QUINOLINE - 1, 10 - DIONES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
| GB9422894D0 (en) * | 1994-11-12 | 1995-01-04 | Zeneca Ltd | Pyridazino quinoline compounds |
| GB9507318D0 (en) * | 1995-04-07 | 1995-05-31 | Zeneca Ltd | Alpha substituted pyridazino quinoline compounds |
-
1994
- 1994-10-12 IL IL11126694A patent/IL111266A/xx not_active IP Right Cessation
- 1994-10-12 GB GB9420590A patent/GB9420590D0/en active Pending
- 1994-10-20 DE DE69426422T patent/DE69426422T2/de not_active Expired - Fee Related
- 1994-10-20 EP EP94930275A patent/EP0724583B1/en not_active Expired - Lifetime
- 1994-10-20 PT PT94930275T patent/PT724583E/pt unknown
- 1994-10-20 SG SG9900943A patent/SG92630A1/en unknown
- 1994-10-20 JP JP51152195A patent/JP3583132B2/ja not_active Expired - Fee Related
- 1994-10-20 DK DK00101917T patent/DK1004582T3/da active
- 1994-10-20 UA UA96041567A patent/UA60291C2/uk unknown
- 1994-10-20 DK DK94930275T patent/DK0724583T3/da active
- 1994-10-20 KR KR1019960702011A patent/KR100261209B1/ko not_active Expired - Fee Related
- 1994-10-20 WO PCT/GB1994/002295 patent/WO1995011244A1/en not_active Ceased
- 1994-10-20 PL PL94314041A patent/PL180679B1/pl not_active IP Right Cessation
- 1994-10-20 RU RU96109470/04A patent/RU2168511C2/ru not_active IP Right Cessation
- 1994-10-20 AT AT94930275T patent/ATE198072T1/de not_active IP Right Cessation
- 1994-10-20 EP EP00101917A patent/EP1004582B1/en not_active Expired - Lifetime
- 1994-10-20 SG SG1996007261A patent/SG59971A1/en unknown
- 1994-10-20 HU HU9600889A patent/HUT74161A/hu unknown
- 1994-10-20 MY MYPI94002796A patent/MY124316A/en unknown
- 1994-10-20 CN CN94194578A patent/CN1053189C/zh not_active Expired - Fee Related
- 1994-10-20 AT AT00101917T patent/ATE295846T1/de not_active IP Right Cessation
- 1994-10-20 ES ES00101917T patent/ES2241513T3/es not_active Expired - Lifetime
- 1994-10-20 DE DE69434380T patent/DE69434380T2/de not_active Expired - Fee Related
- 1994-10-20 ES ES94930275T patent/ES2154686T3/es not_active Expired - Lifetime
- 1994-10-20 AU AU79440/94A patent/AU688393B2/en not_active Ceased
- 1994-10-20 SK SK504-96A patent/SK282491B6/sk not_active IP Right Cessation
- 1994-10-20 US US08/637,641 patent/US5744471A/en not_active Expired - Fee Related
- 1994-10-20 CZ CZ19961138A patent/CZ292311B6/cs not_active IP Right Cessation
- 1994-10-20 SI SI9430476T patent/SI1004582T1/xx unknown
- 1994-10-20 SI SI9430314T patent/SI0724583T1/xx unknown
- 1994-10-20 MY MYPI98002508A patent/MY132875A/en unknown
- 1994-10-20 PT PT00101917T patent/PT1004582E/pt unknown
- 1994-10-20 CA CA002171332A patent/CA2171332A1/en not_active Abandoned
- 1994-10-20 NZ NZ275472A patent/NZ275472A/en not_active IP Right Cessation
- 1994-10-20 NZ NZ329303A patent/NZ329303A/xx not_active IP Right Cessation
- 1994-11-18 TW TW083110721A patent/TW406082B/zh not_active IP Right Cessation
-
1996
- 1996-04-18 FI FI961696A patent/FI113865B/fi active
- 1996-04-19 NO NO961584A patent/NO306995B1/no not_active IP Right Cessation
-
1997
- 1997-03-03 FI FI970907A patent/FI114916B/fi active IP Right Grant
-
1998
- 1998-03-19 US US09/044,109 patent/US6232313B1/en not_active Expired - Fee Related
- 1998-05-27 AU AU68999/98A patent/AU721139B2/en not_active Ceased
-
1999
- 1999-12-06 US US09/455,096 patent/US6103721A/en not_active Expired - Fee Related
-
2000
- 2000-12-14 GR GR20000402690T patent/GR3035080T3/el not_active IP Right Cessation
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0516297B1 (en) * | 1991-05-09 | 1996-10-30 | Zeneca Limited | Pyridazinediones and their use in the treatment of neurological disorders |
| EP0512817B1 (en) * | 1991-05-09 | 1997-02-19 | Zeneca Limited | Pyridazinedione derivatives, their preparation and pharmaceutical applications |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB9420590D0 (en) | Pyridazino quinoline compounds | |
| ATE206412T1 (de) | Heterocyclische verbindungen als bradykinin antagonisten | |
| ATE237596T1 (de) | Chinazolinderivate und deren verwendung als vegf hemmer | |
| EA199900927A1 (ru) | Трициклические соединения | |
| ES8600288A1 (es) | Un procedimiento para la preparacion de derivados de quinolina. | |
| HU9203002D0 (en) | Method for producing tricyclic heterocyclic compounds | |
| GR3030506T3 (en) | 1-azaadamantane derivatives as 5-ht agonists or antagonists. | |
| DE69207182D1 (en) | Antitumor anthracenderivate | |
| DE69316392D1 (de) | Azanoradamantane | |
| DE3882629D1 (de) | Azachromanderivate. | |
| HU900728D0 (en) | Process for preparation of calcium antagonistics | |
| EA199800062A1 (ru) | Новые гетероциклические соединения для лечения боли и их применение | |
| FR2342063A2 (fr) | Nouveaux acetamidoximes, leur procede de preparation et leur application en therapeutique | |
| FI954340A7 (fi) | Menetelmä uusien terapeuttisesti käytt¦kelpoisten 5-substituoitu tia-sykloalka-ÄdÜ-1,2,4-triatsoloÄ1,5-aÜpyrimidiinijohdannaisten valmistamiseksi |